ACADIA Pharmaceuticals Inc at Citizens JMP Life Sciences Conference Transcript
Excited to be joined for our next fireside discussion with ACADIA by ACADIA Pharmaceuticals. With us, we have Kimberly Manhard, the SVP of Global Strategic Planning and Execution; and Mark Schneyer, the CFO. So Mark, Kimberly, I really appreciate you guys being here. I'll just turn it over to give a quick intro and then we'll jump into the Q&A.
Yes, sure. Thanks for that, Jason. We're very happy to be here.
At ACADIA, we have -- we're a commercial stage biotech company. We have 2 first-in-class assets in the market that are first and only approved treatments for their therapies. So NUPLAZID for Parkinson's disease psychosis and DAYBUE for Rett syndrome. And then behind that, we have a pipeline both of disclosed and undisclosed programs to support long-term and future growth. Our 2 late-stage assets are ACP-101 for Prader-Willi syndrome and ACP-204 for
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
